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Abstract: 
Extensive research has demonstrated the potential effectiveness of curcumin against various 
diseases, including asthma and cancers. However, few studies have used liquid-based 
vehicles in the preparation of curcumin formulations. Therefore, the current study proposed 
the use of nanoemulsion and microsuspension formulations to prepare nebulised curcuminoid 
for lung delivery. Furthermore, this work expressed a new approach to understanding the 
aerosol performance of nanoparticles compared to microsuspension formulations. The 
genotoxicity of the formulations was also assessed. Curcuminoid nanoemulsion formulations 
were prepared in three concentrations (100, 250 and 500 µg/ml) using limonene and oleic 
acid as oil phases, while microsuspension solutions were prepared by suspending 
curcuminoid particles in isotonic solution (saline solution) of 0.02% Tween 80. The average 
fine particle fraction (FPF) and mass median aerodynamic diameter (MMAD) of the 
nebulised microsuspension formulations ranged from 26% and 7.1 µm to 40% and 5.7 µm, 
for 1000 µg/ml and 100 µg/ml respectively. In a comparison of the low and high drug 
concentrations of the nebulised nanoemulsion, the average FPF and MMAD of the nebulised 
nanoemulsion formulations prepared with limonene oil ranged from 50% and 4.6 µm to 45% 
and 5.6 µm, respectively; whereas the FPF and MMAD of the nebulised nanoemulsion 
prepared with oleic acid oil ranged from 46% and 4.9 µm to 44% and 5.6 µm, respectively. 
The aerosol performance of the microsuspension formulations were concentration dependent, 
while the nanoemulsion formulations did not appear to be dependent on the curcuminoids 
concentration. The performance and genotoxicity results of the formulations suggest the 
suitability of these preparations for further inhalation studies in animals. 
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1. Introduction  
Curcuminoids are polyphenolic compounds that are extracted from rhizomes of turmeric [1]. 
The alcoholic extracts of turmeric contains three curcuminoids, namely curcumin (77%), 
demethoxycurcumin (18%) and bisdemethoxycurcumin (5%) [2]. Curcuminoids have strong 
anticancer activities [3-6, 47]. Also, several recent studies have reported the potential anti-
asthmatic property of curcumin due to the anti-inflammatory of curcuminoids [7-9]. 
Inhalable curcumin particles has been recently reported in few studies as dry powder inhalers 
using different methods, such as supercritical CO2-assisted spray-drying [10,56], 
supercritical anti-solvent (SAS) precipitation[57], spray and freeze drying [11],   mechanical 
milling followed by spray drying [12,48], nanocomposite particles [13], polymeric micelle 
based [14,47]. Several studies have reported the use of liquid-based vehicles (liposomes and 
Janus nanoparticles) in preparing curcumin formulations for potentially treating lung cancer. 
However, some of these studies (46, 49) have not considered the aerodynamic profile of 
curcumin particles. On the other hand, Manconi et al (50) reported an improvement of the 
curcumin deposition in the stages of a cascade impactor (≥50%) using chitosan coated 
liposomes. Additionally, Manca et al (51) reported that chitosan-glycerosomes may be used 
as lung delivery systems for curcumin, which improves curcumin’s antioxidant and anti-
inflammatory activity. However, further studies may be required to assess the safety of using 
chitosan as a carrier to lung therapeutics. 
In general, microsuspension is the only approved solution formulation for inhaled neutral 
lipophilic drugs that are used for the treatment of asthma and chronic obstructive pulmonary 
disease (COPD) (55). Therefore, the nebulised formulations of the water-insoluble neutral 
compounds available in the market are in suspension form, such as budesonide 
microsuspension. However, several disadvantages of using microsuspension for inhalation 
have been reported, such as considerable drug concentration heterodispersity in the aerosol 
droplets [15], short drug-residence time in the lungs due to ciliary movement [16], limited 
bioavailability of the micronized drug compared to the nanoparticles, and variability in the 
drug deposition patterns when different nebulisers are used [17].  
Therefore, curcuminoid nanoemulsion formulations have been considered and optimized for 
inhalation in this study. Besides, it was reported that curcumin’s anti-inflammatory 
characteristics are improved in nanoemulsion formulations [18]. Oleic acid and limonene oils 
were used to prepare the nanoemulsion formulations, and Tween 80 was used as a surfactant. 
Oleic acid is approved by the FDA for use in respiratory preparations at a concentration of 
0.28%. Tween 80 is also approved for use at 0.02%. In addition, it has been reported that 
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limonene does not cause respiratory irritation or symptoms related to the central nervous 
system when inhaled by human subjects (53), and it reduces airway inflammation in mice 
(54). 
In this study, a curcuminoid suspension formulation was also prepared to examine the 
difference in the aerodynamic behaviour of nanoemulsion and suspension when nebulised. It 
is worth noting that no previous studies have conducted an in-vitro aerodynamic 
characterization of all the curcuminoid components, i.e. curcumin, demethoxycurcumin and 
bisdemethoxycurcumin. 
However, nanoparticles have a potential harmful side effect in humans, they could be 
genotoxic [19, 20], which may be attributed to a direct interaction between the nanoparticles 
and genetic material, indirect damage from nanoparticle-induced reactive oxygen species, or 
by releasing toxic ions [21, 22]. Due to their unique size, nanoparticles have the ability to 
cross the cellular membrane and may reach the nucleus through diffusion across the nuclear 
membrane or transportation through the nuclear pore complex and direct interaction with 
DNA [23].  
Genotoxicity tests of pharmaceutical products before commercialization are required by 
regulatory agencies worldwide [24]. Therefore, the in-vitro genotoxicity of the curcuminoid 
nanoemulsion was examined using single-gel electrophoresis (comet assay) on human 
lymphocyte cells. 
This work proposes the preparation of a curcuminoid nanoemulsion using an extremely low 
amount of surfactant to avoid formulation toxicity, making the nanoemulsion safe for 
inhalation. Additionally, this study addresses a new approach to understanding the aerosol 
performance of nanoparticles compared to microsuspension formulations.  
 
2. Methods 
2.1 Formulation 
Nanoemulsion Preparation: 
Nanoemulsion formulations were prepared using different types of oil including limonene 
and oleic acid. Tween 80 and ethanol were used as surfactant and cosurfactant, respectively. 
(see table 1). The oil (limonene or oleic acid) containing the appropriate concentration of 
drug, surfactant (Tween 80) and cosurfactant (ethanol) were initially mixed and the aqueous 
phase was then added and mixed well in the mixture. The solution was then sonicated for 10 
minutes to ensure that all ingredients had been mixed very well and the nanoemulsion is 
formed. 
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Loading capacity of nanoemulsion was studied by adding an excess amount of curcuminoid 
and then sonicated for 15 mins and left at room temperature for 24 hours. The nanoemulsion 
was then filtered using 0.45 µm syringe filter and diluted in a HPLC mobile phase then 
injected into HPLC.   
 
Microsuspension Preparation 
Saline solution was prepared by dissolving 0.9% of sodium chloride in ultrapure water. A 
sufficient amount of micronized curcuminoids was suspended in 0.2% (w/w) of Tween 80 
and then diluted with saline solution to obtain a 0.02% of tween 80 with final concentration 
of 500, 250 and 100 µg/ml of curcuminoids. The suspension remained homogenous after 
shaking for the period of filling the nebulised chamber and during nebulisation time. The 
amount of Tween 80 was used according to FDA regulations. 
 
2.2 Osmolality  
The osmolality of the nanoemulsion samples was determined at room temperature using 
Advanced 3320 Micro-Osmometer (Model 3320). The Osmometer was calibrated using a 
standard solution (50 mOsm Calibration Standard). Samples were measured in triplicate and 
the mean was then calculated. Sodium chloride was used to adjust the osmolality of the 
samples. 
 
2.3 Particles size measurement 
The particle sizes of the curcumin formulation samples for this study were determined using 
the Malvern Zetasizer Nano-ZS dynamic light scattering (DLS) instrument (Malvern 
Instruments, UK). A suitable volume of undiluted formulation solution was transferred into 
malvern cuvette cell. The mean particle size was determined from three measurements. 
Nanosphere
TM
 (catalogue no. 3060A, mean diameter 59.0nm±2.5) and Duke Standards
TM
 
(catalogue no. 8050, diameter 500.0nm±0.02) were used to calibrate the Zetasizer’s 
performance. 
 
2.4 Viscosity 
The viscosity of the samples was measured using vibrating viscometer (SV-10) at 25
 °
C. The 
sample was loaded into viscometer container (35 ml) and attached into the base of the 
instrument. 
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2.5 Aerosol output  
The method reported by [25]  was used to assess the aerosol output of the nanoemulsion 
using the Sidestream jet nebuliser. Each sample was run in triplicate (n=3); the mean and the 
SD were calculated. Among all samples the amount and the percentage of the inhaled, 
exhaled and remaining drug in the nebuliser chamber were calculated. 
 
2.6 Aerodynamic diameter measurements and particles lungs depositions 
Next Generation Impactor (NGI) was used to characterise the aerodynamic particles size of 
nebulised formulations. According to Pharmacopeia (USP 2012, Ph. Eur 2012), NGI was 
placed in a cooler system at 5
°
C for 30 mins before nebulisation. The jet Sidestream nebuliser 
was kept outside the cooler system and connected to the NGI by T-piece. The NGI was 
connected from the other side to a flow controller which was already attached to a vacuum 
pump. The flow rate was adjusted to be 15 L/min. The pump and the flow controller were 
switched on before starting the nebulisation. The nebuliser chamber was filled with 5 ml of 
nanoemulsion samples and run after switching the pump and the controller on. The 
nebulisation was stopped first after the sputtering sound is heard and then the controller and 
the pump. The NGI cups and the nebuliser chamber were then washed with 20 ml of the 
emodine solution (internal standard). Samples were assessed in triplicate and the nebulisation 
time for each one was recorded. 
 
2.6.1 Data analysis 
Copley Inhaler Testing Data Analysis Software (CITDAS) was used to identify the 
aerodynamic characteristics of the emitted dose. The fine particle dose (FPD) was the amount 
with particles that correspond to a size less than 5m. The fine particle fraction % (FPF) was 
the FPD expressed as a percentage of the total amount deposited into the throat and stages of 
the cascade impactor (this is the dose exiting the mouthpiece) as well as expressed as a 
percentage of the nominal dose (label claim). The mass median aerodynamic diameter 
(MMAD) was the diameter corresponding to 50% undersize. The geometric standard 
deviation (GSD) was the square root for the size corresponding to 84.13% less than the stated 
size divided by the square root of the size for 15.87% (United States Pharmacopeia 2005).  
 
2.7 Genotoxicity: 
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Comet assay is a simple and sensitive method for the detection of DNA breakage in 
individual cells [26]. This method was produced by Ostling and Johanson [26] and it has been 
developed further by Singh and Olive [27, 28]. 
 
 It has been found that DNA damages (fragments) stretches from the nucleus, in the form of a 
comet, toward the anode in alkaline electrophoresis gel. The DNA migration is the function 
of the intensity of DNA breakage. Tail moment, a measure of tail length and the fraction of 
DNA in the Comet tail, was used as the arbitrary unit of assessment [29, 30]. Tail moment 
measures both the smallest detectable size of migrating DNA (reflected in the comet tail 
length) and the number of relaxed / broken pieces of DNA (represented by the intensity of 
DNA in the tail) 
                                                        
The assay was carried out using lymphocytes cells because they are exposed to different 
environments within the body while travelling in the bloodstream and can therefore reflect 
DNA damage that has been induced by endogenous and exogenous genotoxins. These cells 
are  excellent carriers to use in examining the genomic sensitivity of any cell as their sub-
populations have a lengthy life spans and are capable of carrying mutagen-induced genetic 
aberrations for over 40 years [31]. In addition, the World Health Organisation/International 
Programme on Chemical Safety has reported that lymphocytes are suitable surrogate cells for 
cancer [32].Furthermore, Najafzadeh et al., reported that lymphocytes are not only suitable 
surrogates for cancer but for other disease states as chronic obstructive pulmonary disease 
(COPD) and asthma [45], because the DNA is the same in all the cells of an individual. 
 
Comet assay was utilised to study the genotoxcity of nanoemulsion formulations of 
curcumnoids using the protocol that was reported by Tice [33]. All experiments of the 
genotoxicity study were conducted under the Human Tissue Authority License No. 1219 to 
School of Life Sciences. 
Protocol of genotoxicity studies:  
A glass slide was covered with 1 % normal melting point agarose (NMP) and left to dry 
overnight. 890 µl PRMI 1640 was added into Eppendorf tube, 10 µl of curcumin 
nanoemulsion (NE3, NE4, NE5, NE9, NE10 and NE11) was added to the cell media then 100 
µl of whole blood sample was added to the previous mixture and incubated for 30 mins at 37 
˚C. The samples were moved to a centrifuge for 5 mins at 3000 rpm. 900 µl from the 
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supernatant was removed from the samples and 100 µl of 0.5 % low melting point of agarose 
(at 40 0C) was added to each sample. The cell pellets were disrupted gently and 100 µl of the 
suspended cells was transferred into previously coated glass slide with 1 % NMP and 
distributed uniformly  by placing  a cover slip, and left on ice for around 5 min. The cover 
slip was removed carefully and the slide was immersed in a lysis solution (2.5 M NaCl, 100 
mM EDTA, 10 mM Tris, 10% DMSO, 1% Triton X-100, pH 10) at 4 ˚C for overnight. The 
slide then transferred into gel electrophoresis tank with cold alkaline buffer solution (300 mM 
NaOH, 1 mM EDTA, pH <13) and left for about 30 mins at 4 ˚C. The electrophoresis was 
conducted at 25 voltages and 300 mA for 30 min at 4 ˚C. The sample slides were rinsed 
thrice with neutralising buffer solution (400 mM Tris, pH 7.5) and left for 5 min.  Ethidium 
bromide (60 µl, 20µg/ml) was added into the sample slides and a cover slip applied. After 
incubation at room temperature for 5 min the slides were examined with a fluorescent 
microscope equipped with CCD camera. A computerised image analysis system, Komet 4.0 
(Kinetic Imaging, Liverpool, UK), was employed to measure the Comet parameters; the % 
Olive tail moment was then used for statistical analysis. The data was analysed using one-
way ANOVA. 
 
3. Results  
3.1 Nanoemulsion preparation and optimization 
Table 1 shows the visual observation of the nanoemulsion preparations. The limonene 
nanoemulsion was transparent and clear in all formulations. The oleic acid nanoemulsion was 
not formed with 0.8% of oleic acid as oil, so the oil percentage was reduced gradually to 
0.3% to obtain a clear transparent nanoemulsion (Table 1). It was found that the minimum 
amount of surfactant that could form a nanoemulsion was 0.33% (NE5 & NE11). The 
cosurfactant (ethanol) also was reduced from 6.6% (in NE1 & NE7) to 0.25% (in NE5 & 
NE11). There were no changes in nanoemulsion appearance when the surfactant, cosurfactant 
and oil were reduced to the minimum (Table 1). However, the nanoemulsion did not form 
when reducing the percentage of the Tween 80 or ethanol less than 0.33% and 0.25%, 
respectively; this was due to insufficient amounts of surfactant and cosurfactant to solubilise 
the oil.  
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The loading capacity of curcuminoids in nanoemulsion formulations NE9, NE10 and NE11 
was 500, 250 and 100µg/ml of curcuminoids, respectively. The loading capacity of NE3, 
NE4 and NE5 was 500, 250 and 100µg/ml, respectively.   
 
3.2 Osmolality 
The suitable osmolality of aerosol solutions should be between 130 and 500 mOsm/kg, and 
the formulation should also have permeant ions (such as chloride) in concentrations of 31mM 
to 300 mM to ensure the airway’s tolerability of such a formulation [34]. 
From the results in Table 2, it is clear that all of the nanoemulsion and suspension 
formulations (with curcuminoid concentrations of 500, 250 and 100 µg/ml) are in the ideal 
range for osmolality. The only formulations out of the accepted osmolality range for 
nebulisation are NE2 and NE8; this is attributed to a high amount of ethanol in the 
formulations. The ethanol forms 2.5% of the formulations NE2 and NE8. Therefore, these 
formulations with high osmolality and zero sodium chloride were excluded from further 
studies. 
 
3.3 Viscosity 
Viscosity is the resistance of the fluid to a flow; therefore, the viscosity is important in 
aerosol formulations. Ingredients of the formulations and concentration of the drugs may 
change the viscosity of the preparations; hence this could alter the aerosol output and the 
aerodynamic distribution of the particles [34, 35]. The results (Table 2) show that the 
viscosity of the nanoemulsion formulations with either limonene oil or oleic acid oil increases 
as the concentration of ingredients (oil, surfactant and cosurfactant) increases. The results of 
this study show that, as viscosity increases, MMAD increases, which negatively affects the 
aerosol performance. The relationship between the curcumin nanoemulsion formulations’ 
viscosity and MMAD values was linear, with an R
2
 of 96 for the formulation containing oleic 
acid and an R
2
 of 95 for the formulation containing limonene. This finding agrees with the 
report from Mccallion et al (52), which states that droplet size is proportional to the viscosity 
of the nebuliser solution, and more viscous fluids have lower outputs. It has also been 
reported that it is impossible to nebulise highly viscous fluids (> 6cP) [35]. On the other 
hand. The suspension formulation did not show any increase in viscosity, this is because of 
the amount of surfactant used in each formulation, which was constant (0.02 % w/w).  
 
3.4 Particle size analysis using Malvern (Zetasizer) 
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The particle size of the nanoemulsion prepared using limonene oil (NE3, NE4 and NE5) was 
smaller than the nanoemulsion produced by oleic acid (NE9, NE10 and NE11). The 
difference in the particle droplet size can be attributed to the difference in physicochemical 
properties of the oils (viscosity). The viscosity of limonene is about 0.923mPa at 25
0
C [36],
 
whereas the viscosity of oleic acid is 30mPa at 25
0
C [37]. Increasing the viscosity of the fluid 
increases the resistance to the deformation of the particles, hence the oleic acid is more 
resistant to being deformed (dispersed into smaller droplet size) than limonene oil. The 
viscosity of oils has a significant effect on the droplet size of emulsions, as a less viscous oil 
produces a smaller droplet size of emulsion [38, 39]. The particle size of the microsuspension 
was about 1.6µm, which was the same as for micronized solid particles of curcuminoids that 
were prepared beforehand and then suspended in ultrapure water containing Tween 80 and 
0.9% sodium chloride. The results on particle size of the nanoemulsion and suspension 
formulations are given in Table 3. 
 
3.5 Aerosol output using the jet nebuliser 
When comparing the nanoemulsion with the suspension formulations, (Table 4, 
Supplementary Tables 1 and 2), there is a significant increase in the performance of the 
curcuminoid nanoemulsion formulations (either with limonene or oleic acid oil) over the 
suspension preparations. In the suspension formulations, the percentage of the drug left in the 
nebuliser chamber was almost 50% of the delivered dose, whereas in the nanoemulsion it was 
about 30%. Also, the percentage of drug in the inhalation filter from the nanoemulsion 
preparation ranged from 33% to 37%, whereas in the suspension formulation it was about 
21% to 27%.  
 
3.6 Aerodynamic particle size characterization 
Suspension formulations 
The results of a low FPF and high MMAD indicate poor performance for a high drug 
concentration of suspension during nebulisation (Figures 1 & 2, Table 5). The results show 
that the suspension formulation containing curcuminoids at a concentration above 500 µg/ml 
is not suitable for inhalation due to low FPF (%) and high MMAD. These findings are in 
agreement with Amani’s (34) results reported for commercial budesonides suspension using a 
jet nebuliser device.  However, the same formulation with a lower drug concentration showed 
better performance in FPF (%) and MMAD.  
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Nanoemulsion formulations  
The results of aerodynamic characterization of the nanoemulsion formulations using oleic 
acid and limonene for curcumin and demethoxycurcumin and bisdemethoxycurcumin (Tables 
6 & 7) illustrate an improvement in FPF (%) and MMAD compared to suspension 
formulations. Figures 4 and 5 show that the variation in MMAD and FPF was very small 
throughout the nanoemulsion formulations for different curcuminoid concentrations. 
 
3.7 Curcuminoid nanoemulsion genotoxicity study 
Nanoemulsion of curcuminoid genotoxicity (DNA damage) has not been examined before. 
The genotoxicity of the optimised nanoemulsion formulations (NE3, NE4,NE5,NE9,NE10 
and NE11)  is presented in Figure 7. One-way ANOVA analysis (Supplementary Tables 3) 
reveals absence of any genotoxicity with any of the concentrations of limonene and oleic acid 
used in the current study. In fact the DNA damage observed was lower than that of the 
negative control indicating some genoprotective effect of the curcumin nanoemulsions.   
 
4. Discussion 
The study target was to prepare a nanoemulsion vehicle with the lowest possible amount of 
ingredients (i.e. surfactant, cosurfactant and oil). Therefore, each nanoemulsion component 
was decreased to the minimum. To date, all reported nanoemulsion formulations [40-42] have 
been prepared using a high concentration of surfactant (about 10% w/w of the formulation or 
above), which is not suitable for the lungs according to the FDA (US Food and Drug 
Administration). Whereas, in this work, the amount of Tween 80 (surfactant) used was ten to  
thirty times lower than the levels used in other reported work, which could be suitable and 
safer for the respiratory system. 
The performance of aerosol output for the nanoemulsion was much better compared to 
suspension formulations. This finding is in agreement with previous studies done on 
nanoemulsion of budesonide [40]. The low FPF (%) and large MMAD obtained for the 
microsuspension formulations using Sidestream jet nebuliser as well as the large amount of 
the drug left in the nebuliser chamber show that the microsuspension type of formulations is 
inefficient for nebulisation of curcumin, compared with nanoemulsion formulations. 
The authors of this manuscript proposed that the superior output performance of 
nanoemulsion over suspension is due to the fact that the particle size of the nanoemulsion is 
smaller than the particle size in the suspension formulation. Furthermore, the nanoemulsion 
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exists in liquid form and the nebulised droplet will be fully filled with a liquid form, rather 
than solid form (suspension). The results (Table 4, Supplementary Tables 1 and 2) also show 
an improvement in the inhalation rate of nanoemulsion formulations over suspension 
formulations, which are an important factor in regard to patient compliance, because of the 
duration required for the nebulised dose to be taken.  
The enhanced performance of suspension formulations with low drug concentration could be 
due to the fact that nebulisers produce a droplet size ranging from 1 to 5 µm in diameter [43]. 
These droplets usually carry the drug particles during nebulisation. In our opinion, nebulised 
droplets at low drug concentrations carry the drug particles based on the actual size of the 
suspended drug particles (1.6 µm). For example, if the drug has a particle size of 1.6 µm, it 
will likely reside in a nebulised droplet size of 2 µm or above, as illustrated in Figure 3. 
However, at higher drug concentrations, as the number of drug particles increases, the 
nebulised droplets are forced to carry more drug particles within droplets. Consequently, 
more particles have to move at the same time inside the large droplets, which leads to particle 
agglomeration and hence increases their size (for example, if the individual particle has a size 
of 1.6 µm, the agglomerated size may be 2.5 µm or bigger). Therefore, the small droplets will 
remain unoccupied and free from the agglomerated drug particles. This theory could explain 
the poor aerosolized performance with low FPF and large MMAD of the formulated 
microsuspension with high drug concentrations. Similar aerosolized performance was 
reported by Hemmandez-Trejo [44]. They found the agglomeration of particles in a 
suspended solution to be a significant issue during nebulisation from a jet nebuliser. 
The difference in the aerodynamic performance between the nanoemulsion and suspension 
formulations is attributed to the particle size of the drug in each formulation. Our theory for 
explaining this difference in aerodynamic performance between suspension and 
nanoemulsion formulations is that when the drug is in a suspension form, it will occupy the 
nebulised droplet based on the drug particle size. For example, if the drug particles are 1.6-2 
µm, the drug will be carried in the larger nebulised droplet only, as is shown in Figure 6, 
therefore the smaller nebulised droplets will be free of the drugs. Consequently, the 
microsuspension formulations exhibit a lower FPF (%) and higher MMAD. In the case of 
nanoemulsion, the particles are very small in size (12 to 35 nm) and the particle size is more 
uniform, therefore all nebulised droplets will be fully filled with nanoparticles of the drug. 
For these reasons, nanoemulsion formulations exhibited much better fine particle fractions 
(FPF) and hence achieved deeper particle deposition compared to the microsuspension 
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formulation. Additionally, Amani et al., studied the performance of a nebulised nanoemulsion 
formulations containing budesonide in comparison to that of a microsuspension formulations 
of budesonide. The authors found the aerosolization performance of the nanoemulsion 
formulations to be superior to that of the microsuspension formulations because of the 
smaller mass median aerodynamic diameter (MMAD) and larger respirable fraction (FPF) 
values, and this agrees with our findings. However, Amani et al. did not discuss the reason 
for the improved performance of the nanoemulsion formulations. The theory we propose 
provides an explanation for the improved performance that was achieved with the 
nanoemulsion formulations than with the microsuspension formulations in both our study and 
the study reported by Amani et al. [40]. 
The data from the genotoxicity study indicates that the lymphocyte cells experienced no 
genotoxicity during treatment with the curcuminoid nanoemulsion formulations compared to 
the negative control. Garbuzenko et al. [49] supports these findings; however, the authors 
used a different technique to simultaneously encapsulate both curcumin and doxorubicin and 
did not assess the genotoxicity of the individual compounds. In addition, Garbuzenko et al. 
[49] evaporated the emulsion for 6 hrs to remove the organic solvent, which is a long process 
time. The Olive Tail moment in the curcuminoid nanoemulsion formulations was lower than 
in the negative control, indicating that the curcuminoid nanoemulsion formulations may have 
a protective effect and may be able to repair existing damages. Moreover, the DNA seems to 
be intact in the optimised formulations as no DNA comet was found (Figure 8). 
 
5. Conclusion 
The in-vitro aerosolized performance of nanoemulsion was superior to suspension 
formulations and was independent of drug concentration, whereas the performance of the 
suspension was drug concentration dependent.   A theory of understanding the superlative 
aerosol performance of the nanoemulsion formulations over the microsuspension was 
provided and clearly explained.It was further supported by examining the physical properties 
(such as particle size) of the formulations of both types (nanoemulsion and microsuspension). 
Further investigations of this theory is in progress for aerosol nano-suspension formulations.  
The nanoemulsion formulations  prepared with limonene oil and oleic acid were found to be  
nontoxic at the curcuminoid doses that were used in the genotoxicity study. Therefore, this 
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could be an indication of the safety and suitability of the nanoemulsion formulation which 
could be extended  to further investigations for both animals and humans. 
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Figures: 
 
Figure 1. Relationship between the suspension concentrations and the fine particle dose 
fraction of curcuminoids. 
BDC: Bisdemethoxycurcumin; DC: Demethoxycurcumin; C:Curcumin; FPF: Fine particle 
fraction 
 
 
Figure 2. Relationship between the suspension concentrations and the mass median 
aerodynamic diameter (MMAD) of curcuminoids. 
BDC: Bisdemethoxycurcumin; DC: Demethoxycurcumin; C:Curcumin; FPF: Fine particle 
fraction. 
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Figure 3. Nebulised droplets from microsuspension formulations at low drug concentration 
(A) and at high drug concentration (B) 
  : Nebulised droplets. 
 : Suspended drug particles (1.7 µm). 
 
 
 
Figure 4. Relationship between drug nanoemulsion concentrations and FPF and MMAD of 
curcuminoids.  A: MMAD with oleic acid (NE9, NE10, NE11); B: MMAD with limonene 
(NE3, NE4, NE5); C: FPF with oleic acid (NE9, NE10, NE11); D: FPF with limonene (NE3, 
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NE4, NE5).BDC: Bisdemethoxycurcumin; DC: Demethoxycurcumin; C:Curcumin; FPF: 
Fine particle fraction 
 
Figure 5. Comparison of fine particle fraction (FPF) between nanoemulsion formulations and 
suspension for different concentration of curcuminoids (100, 250,500 µg/ml). A: suspension 
3, NE5 and NE11 for curcuminoids of 100µg/ml; B: suspension 2, NE4 and NE 10 for 
curcuminoids of 250µg/ml; C:  suspension 1, NE3 and NE9 for curcuminoids of 500µg/ml. 
BDC: Bisdemethoxycurcumin; DC: Demethoxycurcumin; C:Curcumin 
 
 
 
 
 
 
 
 
 
Figure 6. Nebulised droplets from nanoemulsion formulation (A) and from microsuspension 
formulation (B). 
 
 : Nebulised droplets. 
 : Nanoemulsion particles with the drug (35-12 nm) 
    : Suspended drug particles (1.7 µm). 
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Figure 7. Effect of curcuminoids nanoemulsion formulations on lymphocyte’s DNA.  A: 
limonene oil (NE3, NE4, NE5); B: oleic acid oil (NE9, NE10, NE11). 
Positive control: Hydrogen peroxides (50µg/ml), NC: negative control, PC : positive control, 
CN: curcuminoids nanoemulsion 
Negative control: No drug or reagents used, For more details see the protocol (method, 
section 2.7) 
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0 
1 
2 
NC PC CN (1µg/ml) CN (2.5µg/ml) CN (5µg/ml) 
O
li
v
e 
T
a
il
 M
o
m
en
t 
Effect of curcuminoids limonene nanoemaulsion on DNA 
*** ** 
A 
** 
0 
1 
2 
NC PC CN (1µg/ml) CN (2.5µg/ml) CN (5µg/ml) 
O
li
v
e 
T
a
il
 M
o
m
en
t 
Effect of curcuminoids oliec acid nanoemulsion on DNA 
** ** 
B 
** 
  
 22 
P value <0.05= *  
P value <0.01= **  
P value <0.001= ***  
 
 
 
 
Figure 8. Lymphocyte DNA under a fluorescence microscope after treatment with 
curcuminoids nanoemulsion formulations, A & C: treated with curcuminoids nanoemulsion 
using oleic acid oil at concentration 1 & 5 µg/ml (NE9, NE11). B &D: treated with 
curcuminoids nanoemulsion using limonene oil at concentration 1 & 5 µg/ml (NE3, NE5). 
Image magnification=X20 
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List of Tables: 
Table 1. Nanoemulsion compositions (NE: Nanoemulsion) 
Formulations 
Surfactant% 
(w/w) 
Co-surfactant 
% (w/w) 
Oil % (w/w) 
Water % 
(w/w) 
Visual 
observation 
NE1 Tween 80 (3.3) Ethanol (6.6) Limonene (0.8) Water (89.4) 
Clear 
NE2 Tween 80 (3.3) Ethanol (2.5) Limonene (0.8) Water (93.4) 
Clear 
NE3 Tween 80 (1.6) Ethanol (1.2) Limonene (0.4) Water (96.7) 
Clear 
NE 4 Tween 80 (0.8) Ethanol (0.62) Limonene (0.2) Water (98.4) 
Clear 
NE5 Tween 80 (0.3) Ethanol (0.2) Limonene (0.1) Water (99.2) 
Clear 
NE6 Tween 80 (3.3) Ethanol (6.6) Oleic acid (0.8) Water (89.3) Turbid 
NE7 Tween 80 (3.3) Ethanol (6.6) Oleic acid (0.3) Water (89.8) 
Clear 
NE8 Tween 80 (3.3) Ethanol (2.5) Oleic acid (0.3) Water (93.9) 
Clear 
NE9 Tween 80 (1.6) Ethanol (1.2) Oleic acid (0.1) Water (96.9) 
Clear 
NE10 Tween 80 (0.8) Ethanol (0.6) Oleic acid (0.07) Water (98.4) 
Clear 
NE11 Tween 80 (0.3) Ethanol (0.2) Oleic acid (0.03) Water (99.4) 
Clear 
NE: Nanoemulsion 
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Table 2. Osmolality and viscosity results for the nanoemulsion and suspension preparations  
Formulations 
Concentration of NaCl 
(mM) 
Osmolality 
(mOsm/kg) 
Viscosity 
(mPas) 
pH 
NE 2 (1000µg/ml) 0 600 ± 3 -- -- 
NE3 (500µg/ml) 35 350 ± 2 1.2 7 
NE4 (250µg/ml) 95 345 ± 3 1.1 7 
NE5 (100µg/ml) 150 340 ± 5 1.1 6 
NE8 (1000µg/ml) 0 600 ± 4 -- -- 
NE9 (500µg/ml) 35 353 ± 4 1.2 7 
NE10 (250µg/ml) 95 343 ± 6 1.7 7 
NE11 (100µg/ml) 150 336 ± 2 1.1 6 
Suspension1 (500µg/ml) 160 286 ± 4 1.1 6 
Suspension 2 (250µg/ml) 160 286 ± 3 1.1 5 
Suspension 3 (100µg/ml) 160 284 ± 3 1.1 5 
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Table 3. Particle size results and polydispersity index for nanoemulsion and suspension 
formulations using Malvern Zetasizer  
Formulations Particle size (nm) ± SD PDI 
NE3 (500µg/ml) 13 ± 5 0.1 
NE4 (250µg/ml) 13 ± 3 0.1 
NE5 (100µg/ml) 12 ± 4 0.1 
NE9 (500µg/ml) 39 ± 25 0.2 
NE10 (250µg/ml) 33 ± 18 0.2 
NE11 (100µg/ml) 31 ± 15 0.2 
Suspension 1 (500µg/ml) 1650 ± 1015 0.2 
Suspension 2 (250µg/ml) 1650 ± 1015 0.2 
Suspension 3 (100µg/ml) 1650 ± 1015 0.2 
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Table 4. Aerosol output data of curcumin (C)  that was nebulised from jet nebuliser at dose of 
100, 250 and 500 µg/ml of 5 ml of curcuminiods (n=3) 
Form 
Conct of 
curcuminoi
d) 
% 
Inhal 
% 
Exhal 
% 
Cham 
% 
Con 
Neb 
time 
(min) 
Inhal 
rate 
(%drug/
min) 
Exhal rate       
(%drug/m
in) 
NE 5 
100 µg/ml 
(contains 5 
µg/ml of C) 
34 31 33 1.4 13 2.6 2.4 
NE 11 37 27 31 2.7 13 2.9 2.1 
Suspension 3 28 21 49 1.7 15 1.9 1.4 
NE 4 
250 µg/ml 
(contains 
12.5 µg/ml 
of C) 
33 36 29 1.4 13 2.6 2.8 
NE 10 31 36 30 3.1 12 2.5 2.9 
Suspension 2 27 27 44 2.6 15 1.9 1.8 
NE 3 
500 µg/ml 
(contains 25 
µg/ml of C) 
34 35 30 1.9 13 2.5 2.6 
NE 9 37 34 27 2.4 13 2.9 2.7 
Suspension 1 21 23 54 1.9 15 1.4 1.5 
Form: formulations; Conct: concentration; Exhal: Exhalation; Inhal: inhalation; Cham: chamber; Con: 
connector; Neb: nebulisation 
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Table 5. The mean (n=3) of the aerodynamic data of suspension formulations using jet 
nebuliser at flow 15 L/min 
 
 
FPF %*: the percentage of Fine Particle Fraction. MMAD*: Mass Median Aerodynamic Diameter.  GSD*: 
Geometric Standard Deviation. FPD*: Fine Particle Dose. 
 
 
 
 
 
 
 
Drug Formulation 
FPF 
% 
MMAD (µm) GSD FPD (µg) 
Bisdemethoxycurcumin 
Suspension 3 (100µg/ml) 40 5.8 2.1 12 
Suspension 2 (250µg/ml) 35 6.5 2.2 17 
Suspension 1 (500µg/ml) 33 6.6 2.0 34 
Suspension 4 (1000 g/ml) 26 7.1 2.0 43 
Demethoxycurcumin 
Suspension 3 (100µg/ml) 38 6.1 2.2 18 
Suspension 2 (250µg/ml) 33 6.4 2.1 40 
Suspension 1 (500µg/ml) 31 6.7 2.0 99 
Suspension 4 (1000 g/ml) 25 7.1 2.0 109 
Curcumin 
Suspension 3 (100µg/ml) 43 5.3 2.6 101 
Suspension 2 (250µg/ml) 36 6.2 2.2 152 
Suspension 1 (500µg/ml) 32 6.6 2.1 369 
Suspension 4 (1000 g/ml) 26 7.1 2.0 379 
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Table 6. The mean (n=3) of the aerodynamic characterisation of curcuminoids nanoemulsion 
with oleic acid oil formulations using Jet nebuliser at flow 15L/min 
Drug Formulations FPF % MMAD (µm) GSD FPD (µg) 
Bisdemethoxycurcumin 
NE 11(100µg/ml) 46 4.8 2.3 12 
NE 10 (250µg/ml) 44 5.3 2.3 16 
NE 9 (500µg/ml) 43 5.7 2.1 42 
Demethoxycurcumin 
NE 11(100µg/ml) 44 5.5 2.4 31 
NE 10 (250µg/ml) 43 5.7 2.5 41 
NE 9 (500µg/ml) 42 5.8 2.1 149 
curcumin 
NE 11(100µg/ml) 48 4.3 2.6 161 
NE 10 (250µg/ml) 47 4.8 2.8 182 
NE 9 (500µg/ml) 47 5.2 2.1 585 
 
Table 7. The mean (n=3) of the aerodynamic characterisation of curcuminoids nanoemulsion 
with limonene oil formulations using Jet nebuliser at flow 15L/m 
 
  
Drug Formulations FPF % MMAD (µm) GSD FPD (µg) 
Bisdemethoxycurcumin 
NE 5 (100µg/ml) 51 4.5 2.7 17 
 NE4 (250µg/ml) 46 5.3 2.3 21 
NE 3 (500µg/ml) 45 5.5 2.2 44 
Demethoxycurcumin 
NE 5 (100µg/ml) 47 4.9 2.2 40 
 NE4 (250µg/ml) 46 5.1 2.1 76 
NE 3 (500µg/ml) 44 5.6 2.1 155 
Curcumin 
NE 5 (100µg/ml) 51 4.5 2.4 174 
 NE4 (250µg/ml) 50 4.7 2.2 300 
NE 3 (500µg/ml) 45 5.5 2.2 587 
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